

Ruth Tal-Singer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4921580/publications.pdf>

Version: 2024-02-01

239
papers

17,614
citations

21215

62
h-index

17373

126
g-index

245
all docs

245
docs citations

245
times ranked

16946
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-“Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287.	2.5	72
2	Development of a Blood-based Transcriptional Risk Score for Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 161-170.	2.5	15
3	Quality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective. Advances in Therapy, 2022, 39, 2302-2322.	1.3	5
4	Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1488-1502.	2.5	107
5	The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2021, 147, 158-167.	1.5	102
6	A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD. European Respiratory Journal, 2021, 57, 2002050.	3.1	44
7	Short physical performance battery as a practical tool to assess mortality risk in chronic obstructive pulmonary disease. Age and Ageing, 2021, 50, 795-801.	0.7	12
8	New Adopters of Telemedicine During the Coronavirus-19 Pandemic in Respondents to an Online Community Survey: The Case for Access to Remote Management Tools for Individuals with Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 213-218.	0.5	5
9	Objectively Measured Physical Activity in Patients with COPD: Recommendations from an International Task Force on Physical Activity. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 528-550.	0.5	24
10	Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD. Respiratory Research, 2021, 22, 127.	1.4	26
11	Relationship between Emphysema Progression at CT and Mortality in Ever-Smokers: Results from the COPDGene and ECLIPSE Cohorts. Radiology, 2021, 299, 222-231.	3.6	27
12	Quantitative ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography to assess pulmonary inflammation in COPD. ERJ Open Research, 2021, 7, 00699-2020.	1.1	2
13	Nighttime features derived from topic models for classification of patients with COPD. Computers in Biology and Medicine, 2021, 132, 104322.	3.9	6
14	Utility of Self-Administered Questionnaires for Identifying Individuals at Risk of COPD in Japan: The OCEAN (Okinawa COPD casE finding AssessmeNt) Study. International Journal of COPD, 2021, Volume 16, 1771-1782.	0.9	11
15	A Prospective Cohort Study to Assess Obstructive Respiratory Disease Phenotypes and Endotypes in Japan: The TRAIT Study Design. International Journal of COPD, 2021, Volume 16, 1813-1822.	0.9	4
16	Objectively Measured Physical Activity as a COPD Clinical Trial Outcome. Chest, 2021, 160, 2080-2100.	0.4	17
17	Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationale. ERJ Open Research, 2021, 7, 00201-2021.	1.1	3
18	Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial. ERJ Open Research, 2021, 7, 00253-2021.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Prevalence and Characteristics of Individuals with Preserved Ratio Impaired Spirometry (PRISm) and/or Impaired Lung Function in Japan: The OCEAN Study. <i>International Journal of COPD</i> , 2021, Volume 16, 2665-2675.	0.9	15
20	Genetic variation in genes regulating skeletal muscle regeneration and tissue remodelling associated with weight loss in chronic obstructive pulmonary disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1803-1817.	2.9	11
21	Development of Respercise [®] a Digital Application for Standardizing Home Exercise in COPD Clinical Trials. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 269-276.	0.5	1
22	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2021, 57, 2001339.	3.1	26
23	A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients. <i>European Respiratory Journal</i> , 2021, 57, 2003103.	3.1	38
24	A rapidly changing understanding of COPD: World COPD Day from the COPD Foundation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 321, L983-L987.	1.3	10
25	Clinical Development and Research Applications of the Chronic Obstructive Pulmonary Disease Assessment Test. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1058-1067.	2.5	3
26	The sputum microbiome is distinct between COPD and health, independent of smoking history. <i>Respiratory Research</i> , 2020, 21, 183.	1.4	45
27	CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin. <i>ERJ Open Research</i> , 2020, 6, 00583-2020.	1.1	19
28	Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 696-708.	5.2	69
29	Endotrophin, an extracellular hormone, in combination with neoepitope markers of von Willebrand factor improves prediction of mortality in the ECLIPSE COPD cohort. <i>Respiratory Research</i> , 2020, 21, 202.	1.4	13
30	Multi-omic meta-analysis identifies functional signatures of airway microbiome in chronic obstructive pulmonary disease. <i>ISME Journal</i> , 2020, 14, 2748-2765.	4.4	43
31	Consensus Recommendations on the Use of 18F-FDG PET/CT in Lung Disease. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1701-1707.	2.8	8
32	<p>Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 2467-2476.	0.9	11
33	<p>Co-Morbidity Patterns Identified Using Latent Class Analysis of Medications Predict All-Cause Mortality Independent of Other Known Risk Factors: The COPDGene<sup>®</sup> Study</p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 1171-1181.	1.5	6
34	Negative Food Effect of Danirixin: Use of PBPK Modelling to Explore the Effect of Formulation and Meal Type on Clinical PK. <i>Pharmaceutical Research</i> , 2020, 37, 233.	1.7	8
35	Combining biomarkers of clot resolution and alveolar basement membrane destruction predicts mortality in the ECLIPSE COPD cohort. <i>Respiratory Medicine</i> , 2020, 173, 106185.	1.3	3
36	Heme metabolism genes Downregulated in COPD Cachexia. <i>Respiratory Research</i> , 2020, 21, 100.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Machine Learning and Prediction of All-Cause Mortality in COPD. <i>Chest</i> , 2020, 158, 952-964.	0.4	62
38	CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial. <i>Respiratory Research</i> , 2020, 21, 149.	1.4	44
39	Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 660-671.	2.5	62
40	<p>Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk<p>. <i>International Journal of COPD</i> , 2020, Volume 15, 543-552.	0.9	15
41	Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD. <i>Respiratory Research</i> , 2020, 21, 166.	1.4	44
42	Risk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational study. <i>PLoS ONE</i> , 2020, 15, e0228940.	1.1	13
43	DNA Methylation Is Predictive of Mortality in Current and Former Smokers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1099-1109.	2.5	15
44	Cardiovascular risk prediction using physical performance measures in COPD: results from a multicentre observational study. <i>BMJ Open</i> , 2020, 10, e038360.	0.8	8
45	Clinical endotypes of exacerbation are associated with differences in microbial composition and diversity in COPD. <i>European Respiratory Journal</i> , 2020, 56, 2000391.	3.1	18
46	A high-risk airway mycobiome characterises frequent COPD exacerbators. , 2020, , .		3
47	Short Physical Performance Battery: What Does Each Sub-Test Measure in Patients with Chronic Obstructive Pulmonary Disease?. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 13-25.	0.5	10
48	COPD at the Time of COVID-19: A COPD Foundation Perspective. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 73-75.	0.5	30
49	The COPD Foundation Coronavirus Disease 2019 International Medical Experts Survey: Results. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 139-146.	0.5	1
50	COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development. <i>Respiratory Medicine</i> , 2020, 173, 106175.	1.3	4
51	A combination of biomarkers for fibrinolysis and basement membrane destruction predicts mortality in the ECLIPSE COPD cohort. , 2020, , .		1
52	Effect of long-acting muscarinic antagonist (LAMA) on 24-hour physical behaviours in COPD. , 2020, , .		0
53	Azurocidin-1: a marker of COPD severity and microbial dysbiosis. , 2020, , .		0
54	Detecting shortness of breath remotely and accurately using smartphones and vocal biomarkers. , 2020, , .		2

#	ARTICLE	IF	CITATIONS
55	DSP variants may be associated with longitudinal change in quantitative emphysema. <i>Respiratory Research</i> , 2019, 20, 160.	1.4	7
56	It's more than low BMI: prevalence of cachexia and associated mortality in COPD. <i>Respiratory Research</i> , 2019, 20, 100.	1.4	66
57	Real-world use of rescue inhaler sensors, electronic symptom questionnaires and physical activity monitors in COPD. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000350.	1.2	16
58	Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort. <i>Respiratory Research</i> , 2019, 20, 63.	1.4	23
59	Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients. <i>ERJ Open Research</i> , 2019, 5, 00021-2019.	1.1	4
60	Specific elastin degradation products are associated with poor outcome in the ECLIPSE COPD cohort. <i>Scientific Reports</i> , 2019, 9, 4064.	1.6	18
61	New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. <i>Nature Genetics</i> , 2019, 51, 481-493.	9.4	350
62	Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. <i>Nature Genetics</i> , 2019, 51, 494-505.	9.4	257
63	End-product of fibrinogen is elevated in emphysematous chronic obstructive pulmonary disease and is predictive of mortality in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2019, 160, 105814.	1.3	15
64	Do sputum or circulating blood samples reflect the pulmonary transcriptomic differences of COPD patients? A multi-tissue transcriptomic network META-analysis. <i>Respiratory Research</i> , 2019, 20, 5.	1.4	9
65	Integrative Genomics Analysis Identifies ACVR1B as a Candidate Causal Gene of Emphysema Distribution. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 60, 388-398.	1.4	15
66	Late Breaking Abstract - A connected inhaler system improves adherence to fluticasone furoate/vilanterol in asthma. , 2019, , .		1
67	Lung microbiome dysbiosis is associated with mortality in COPD. , 2019, , .		1
68	Improving symptomology in COPD: which therapy would you choose, a bronchodilator or pulmonary rehabilitation?. , 2019, , .		1
69	COPD Gene 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 384-399.	0.5	112
70	Endotrophin and von Willebrand factor processing as predictive markers for mortality in the ECLIPSE COPD cohort. , 2019, , .		0
71	Late Breaking Abstract - High blood neutrophils are associated with increased exacerbations and mortality in Chronic Obstructive Pulmonary Disease. , 2019, , .		0
72	Missing a signal in exercise outcomes – is ventilatory limitation a factor in COPD?. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
73	Prediction of muscle weakness in COPD: results from modelling using the ERICA cohort. , 2019, , .		0
74	Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study. Thorax, 2018, 73, 1182-1185.	2.7	9
75	Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax, 2018, 73, 422-430.	2.7	201
76	Frailty: A global measure of the multisystem impact of COPD. Chronic Respiratory Disease, 2018, 15, 347-355.	1.0	37
77	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1540-1551.	2.5	185
78	Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. European Respiratory Journal, 2018, 51, 1702146.	3.1	60
79	Surrogate Markers of Cardiovascular Risk and Chronic Obstructive Pulmonary Disease. Hypertension, 2018, 71, 499-506.	1.3	29
80	Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study. Thorax, 2018, 73, 331-338.	2.7	101
81	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2018, 141, 2037-2047.e10.	1.5	138
82	Whole exome sequencing analysis in severe chronic obstructive pulmonary disease. Human Molecular Genetics, 2018, 27, 3801-3812.	1.4	32
83	Vascular inflammation and aortic stiffness: potential mechanisms of increased vascular risk in chronic obstructive pulmonary disease. Respiratory Research, 2018, 19, 100.	1.4	23
84	Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD. European Respiratory Journal, 2018, 52, 1801020.	3.1	48
85	Distribution, temporal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort. Respiratory Medicine, 2018, 141, 14-19.	1.3	12
86	Longitudinal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort. , 2018, , .		1
87	The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial. PLoS ONE, 2018, 13, e0194197.	1.1	23
88	The value of short physical performance battery (SPPB) as an alternative component of the BODE Index in predicting death in chronic obstructive pulmonary disease (COPD) in the ERICA cohort.. , 2018, , .		0
89	Prevalence of physical limitation in COPD: the short physical performance battery (SPPB). , 2018, , .		0
90	Late Breaking Abstract - Overlap of SGRQ and CAT-defined chronic mucus hypersecretion in the SPIROMICS cohort: implications for digital health. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
91	Quantification of Lung PET Images: Challenges and Opportunities. Journal of Nuclear Medicine, 2017, 58, 201-207.	2.8	55
92	Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. Nature Genetics, 2017, 49, 426-432.	9.4	306
93	Analysis of nocturnal actigraphic sleep measures in patients with COPD and their association with daytime physical activity. Thorax, 2017, 72, 694-701.	2.7	46
94	Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 35-46.	1.4	55
95	Danirixin: A Reversible and Selective Antagonist of the CXCR2 Chemokine Receptor 2. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 338-346.	1.3	36
96	Physical activity patterns and clusters in 1001 patients with COPD. Chronic Respiratory Disease, 2017, 14, 256-269.	1.0	56
97	Longitudinal follow-up of quadriceps strength and function in a COPD cohort after 3 years. European Respiratory Journal, 2017, 50, 1700707.	3.1	2
98	Multiple biomarkers predict disease severity, progression and mortality in COPD. Respiratory Research, 2017, 18, 117.	1.4	103
99	Quantitative analysis of dynamic 18F-FDG PET/CT for measurement of lung inflammation. EJNMMI Research, 2017, 7, 47.	1.1	23
100	A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials. Lancet Respiratory Medicine, 2017, 5, 577-590.	5.2	32
101	Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers. Chest, 2017, 151, 555-563.	0.4	62
102	The St. George's Respiratory Questionnaire Appendix to the Food and Drug Administration Draft Guidance on COPD. Chest, 2017, 152, 914-916.	0.4	1
103	The COPD Biomarkers Qualification Consortium Database: Baseline Characteristics of the St George's Respiratory Questionnaire Dataset. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 108-119.	0.5	10
104	St George's Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 137-145.	0.5	20
105	Socioeconomic Status as a Determinant of Health Status Treatment Response in COPD Trials. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 146-154.	0.5	10
106	Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 155-164.	0.5	10
107	Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 120-127.	0.5	8
108	Late Breaking Abstract - Danirixin (GSK1325756) improves respiratory symptoms and health status in mild to moderate COPD - results of a 1 year first time in patient study. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
109	Late Breaking Abstract - Co-morbid disease clusters in chronic obstructive pulmonary disease: the ERICA study. , 2017, , .		0
110	Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. British Journal of Clinical Pharmacology, 2016, 81, 971-979.	1.1	122
111	Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD. BMJ Open Respiratory Research, 2016, 3, e000151.	1.2	36
112	Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2016, 17, 712-718.	1.2	77
113	Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease. European Respiratory Journal, 2016, 48, 1215-1218.	3.1	25
114	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. Respiratory Medicine, 2016, 119, 87-95.	1.3	29
115	High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD – results from the ECLIPSE study. Respiratory Research, 2016, 17, 125.	1.4	57
116	The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1483-1493.	2.5	83
117	Long-term Course of Depression Trajectories in Patients With COPD. Chest, 2016, 149, 916-926.	0.4	61
118	COPD subtypes identified by network-based clustering of blood gene expression. Genomics, 2016, 107, 51-58.	1.3	49
119	A comparison of COPD patients with and without ACOS in the ECLIPSE study. European Respiratory Journal, 2016, 47, 1559-1562.	3.1	35
120	Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. European Respiratory Journal, 2016, 47, 1365-1373.	3.1	64
121	Lung microbiome dynamics in COPD exacerbations. European Respiratory Journal, 2016, 47, 1082-1092.	3.1	330
122	Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in Emphysema. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1242-1253.	2.5	99
123	Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 607-613.	2.5	104
124	LATE-BREAKING ABSTRACT: Network-based meta-analysis of lung, sputum and blood transcriptomics in COPD. , 2016, , .		0
125	Changes in FEV1 over 8 years in COPD. , 2016, , .		0
126	Assessing symptoms in COPD: Use of the E-RS daily digital diary in early drug development. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
127	A functional imaging study to investigate the relationship between pulmonary inflammation and systemic inflammation in COPD patients. , 2016, , .		0
128	Exercise-induced oxygen desaturation determinants including pulmonary emphysema in COPD: ECLIPSE data. , 2016, , .		0
129	A functional imaging study to evaluate aortic inflammation in OSA subjects. , 2016, , .		0
130	LATE-BREAKING ABSTRACT: Cardiovascular and skeletal muscle manifestations in COPD: The ERICA study. , 2016, , .		0
131	Gene expression changes caused by the p38 MAPK inhibitor dilmapirod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial. Pharmacology Research and Perspectives, 2015, 3, e00094.	1.1	15
132	Functional Capacity, Health Status, and Inflammatory Biomarker Profile in a Cohort of Patients With Chronic Obstructive Pulmonary Disease. Journal of Cardiopulmonary Rehabilitation and Prevention, 2015, 35, 348-355.	1.2	8
133	Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. Annals of the American Thoracic Society, 2015, 12, 303-312.	1.5	126
134	Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Biomarker of Emphysema and the RAGE Axis in the Lung. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 785-792.	2.5	82
135	Clinical and prognostic heterogeneity of C and D GOLD groups. European Respiratory Journal, 2015, 46, 250-254.	3.1	11
136	One-year change in health status and subsequent outcomes in COPD. Thorax, 2015, 70, 420-425.	2.7	50
137	The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) a selective CXCR2 antagonist in healthy adult subjects. BMC Pharmacology & Toxicology, 2015, 16, 18.	1.0	46
138	Identifying Physical Activity Profiles in COPD Patients Using Topic Models. IEEE Journal of Biomedical and Health Informatics, 2015, 19, 1567-1576.	3.9	12
139	Low plasma CC16 levels in smokers are associated with a higher risk for chronic bronchitis. European Respiratory Journal, 2015, 46, 1501-1503.	3.1	19
140	Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respiratory Medicine, 2015, 109, 1138-1146.	1.3	77
141	A Genome-Wide Association Study of Emphysema and Airway Quantitative Imaging Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 559-569.	2.5	128
142	Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci. Human Molecular Genetics, 2015, 24, 1200-1210.	1.4	43
143	Safety and pharmacology of a soluble epoxide hydrolase inhibitor. , 2015, , .		1
144	Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients. , 2015, , .		1

#	ARTICLE	IF	CITATIONS
145	Correlation Between Emphysema and Lung Function in Healthy Smokers and Smokers With COPD. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2015, 2, 204-213.	0.5	9
146	LATE-BREAKING ABSTRACT: Biomarkers of tissue turnover are related to annual change in FEV1 in patients with COPD within the ECLIPSE cohort. , 2015, , .		0
147	Evaluation of asthma/COPD overlap within the ECLIPSE study. , 2015, , .		0
148	LATE-BREAKING ABSTRACT: Biomarkers of extracellular matrix turnover predict mortality in the ECLIPSE COPD cohort. , 2015, , .		0
149	Health status predicts long-term outcomes in patients with chronic obstructive pulmonary disease (COPD): Pooled analysis of patient-level data from the COPD biomarker qualification consortium database. , 2015, , .		0
150	S49 Telomere Attrition In Circulating White Blood Cells In Copd Relates To Lung Function And Outcomes. Thorax, 2014, 69, A28-A28.	2.7	0
151	Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 2, 23-34.	0.5	76
152	An Aberrant Leukotriene A ₄ Hydrolase "Proline-Glycine-Proline Pathway in the Pathogenesis of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 51-61.	2.5	55
153	Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulmonary Medicine, 2014, 14, 164.	0.8	55
154	A diVlusive Shuffling Approach (VlStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease. BMC Systems Biology, 2014, 8, S8.	3.0	24
155	Eosinophilic inflammation in COPD: prevalence and clinical characteristics. European Respiratory Journal, 2014, 44, 1697-1700.	3.1	348
156	Common Genetic Variants Associated with Resting Oxygenation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 678-687.	1.4	19
157	S51 Circulating Desmosine Relates To Cardiovascular Comorbidity, Coronary Artery Calcification Score (cacs), Systemic Inflammation And Mortality In Patients With Copd. Thorax, 2014, 69, A28-A29.	2.7	1
158	Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study. Journal of Translational Medicine, 2014, 12, 9.	1.8	46
159	Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax, 2014, 69, 718-723.	2.7	151
160	Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. Respiratory Medicine, 2014, 108, 1647-1654.	1.3	22
161	Evaluating the Role of Inflammation in Chronic Airways Disease: The ERICA Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 552-559.	0.7	12
162	Microfibrillar-associated protein 4: A potential biomarker of chronic obstructive pulmonary disease. Respiratory Medicine, 2014, 108, 1336-1344.	1.3	44

#	ARTICLE	IF	CITATIONS
163	Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2014, 2, 214-225.	5.2	291
164	Lessons from ECLIPSE: a review of COPD biomarkers. <i>Thorax</i> , 2014, 69, 666-672.	2.7	125
165	Should We View Chronic Obstructive Pulmonary Disease Differently after ECLIPSE?. A Clinical Perspective from the Study Team. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1022-1030.	2.5	130
166	Altered Gene Expression in Blood and Sputum in COPD Frequent Exacerbators in the ECLIPSE Cohort. <i>PLoS ONE</i> , 2014, 9, e107381.	1.1	52
167	Systemic Soluble Receptor for Advanced Glycation Endproducts Is a Biomarker of Emphysema and Associated with AGER Genetic Variants in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 948-957.	2.5	138
168	Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2013, 107, 1376-1384.	1.3	328
169	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies. <i>Clinical Drug Investigation</i> , 2013, 33, 477-488.	1.1	20
170	The COPD Biomarker Qualification Consortium (CBQC). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 367-377.	0.7	67
171	Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 241-248.	0.3	102
172	Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: Two randomised studies. <i>European Journal of Pharmacology</i> , 2013, 701, 40-48.	1.7	28
173	The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. <i>Lancet Respiratory Medicine</i> , 2013, 1, 129-136.	5.2	224
174	Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 382-386.	2.5	257
175	Changes in Body Composition in Patients with Chronic Obstructive Pulmonary Disease: Do They Influence Patient-Related Outcomes?. <i>Annals of Nutrition and Metabolism</i> , 2013, 63, 239-247.	1.0	46
176	Reply: Minimal or Maximal Clinically Important Difference: Using Death to Define MCID. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1392-1392.	2.5	5
177	Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease: Table 1. <i>Thorax</i> , 2013, 68, 670-676.	2.7	157
178	Heterogeneity of quadriceps muscle phenotype in chronic obstructive pulmonary disease (<sc>COPD</sc>); implications for stratified medicine?. <i>Muscle and Nerve</i> , 2013, 48, 488-497.	1.0	61
179	Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2013, 42, 636-646.	3.1	164
180	Prospects for the development of effective pharmacotherapy targeted at the skeletal muscles in chronic obstructive pulmonary disease: a translational review. <i>Thorax</i> , 2012, 67, 1102-1109.	2.7	25

#	ARTICLE	IF	CITATIONS
181	Metabolic profiling detects biomarkers of protein degradation in COPD patients. <i>European Respiratory Journal</i> , 2012, 40, 345-355.	3.1	128
182	Genome-Wide Association Analysis of Blood Biomarkers in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 1238-1247.	2.5	117
183	Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. <i>Thorax</i> , 2012, 67, 701-708.	2.7	160
184	Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 291-297.	1.2	193
185	p38 Mitogen-activated Protein Kinase is Not Activated in the Quadriceps of Patients with Stable Chronic Obstructive Pulmonary Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012, 9, 142-150.	0.7	14
186	Physical activity monitoring in COPD: Compliance and associations with clinical characteristics in a multicenter study. <i>Respiratory Medicine</i> , 2012, 106, 522-530.	1.3	136
187	Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1065-1072.	2.5	353
188	A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. <i>Human Molecular Genetics</i> , 2012, 21, 947-957.	1.4	216
189	Fibrinogen, COPD and Mortality in a Nationally Representative U.S. Cohort. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012, 9, 359-366.	0.7	39
190	Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. <i>Molecular BioSystems</i> , 2012, 8, 3125.	2.9	94
191	An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 416-424.	1.0	99
192	Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. <i>International Journal of COPD</i> , 2012, 7, 173.	0.9	22
193	Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. <i>PLoS ONE</i> , 2012, 7, e37483.	1.1	633
194	Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. <i>Respiratory Medicine</i> , 2011, 105, 1069-1078.	1.3	131
195	Evaluation of exhaled breath condensate pH as a biomarker for COPD. <i>Respiratory Medicine</i> , 2011, 105, 1037-1045.	1.3	45
196	One-Year Stability Of Quadriceps Muscle Strength In Patients With COPD: An Eclipse Sub Study. , 2011, , .		0
197	Correlates Of Fibrinogen Levels (Total And Elevated) In A US Cohort. , 2011, , .		0
198	Prediction Of A COPD Exacerbation Phenotype Using Blood Transcriptomic Markers. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
199	3-Year Decline In Forced Expiratory Volume In One Second (FEV1) In The Eclipse Study. , 2011, , .		0
200	Measurement Of Physical Activity In Patients With COPD In A Multicenter Setting: Compliance And Associations With Clinical Characteristics Of The Disease. , 2011, , .		0
201	Genome Wide Association Study Of Exacerbation Phenotypes In COPD. , 2011, , .		0
202	Genetics of Sputum Gene Expression in Chronic Obstructive Pulmonary Disease. PLoS ONE, 2011, 6, e24395.	1.1	59
203	Chronic Cough, Chronic Phlegm And Dyspnea In A Large Observational Cohort Of COPD Patients. , 2011, , .		0
204	Genetics Of Sputum Gene Expression Supports Two Distinct COPD Susceptibility Genes On Chromosome 15q25. , 2011, , .		0
205	Reduced 6MWD Is Associated With Increased Mortality And Exacerbation-Related Hospitalization In COPD: The Eclipse Study. , 2011, , .		1
206	A Genome-Wide Association Study In COPD Identifies A Susceptibility Locus On Chromosome 19q13. , 2011, , .		0
207	Co-Morbidities In COPD, Clinical Associations And Relations To Outcomes. , 2011, , .		0
208	SBâ€656933, a novel CXCR2 selective antagonist, inhibits <i>ex vivo</i> neutrophil activation and ozoneâ€induced airway inflammation in humans. British Journal of Clinical Pharmacology, 2011, 72, 282-293.	1.1	126
209	COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respiratory Research, 2011, 12, 146.	1.4	134
210	Serum PARC/CCL-18 Concentrations and Health Outcomes in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1187-1192.	2.5	93
211	Polymorphisms in Surfactant Proteinâ€D Are Associated with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 316-322.	1.4	83
212	Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax, 2011, 66, 489-495.	2.7	61
213	Changes in Forced Expiratory Volume in 1 Second over Time in COPD. New England Journal of Medicine, 2011, 365, 1184-1192.	13.9	811
214	Genome Wide Association Study Of Body Mass Index And Fat Free Mass Index In COPD. , 2010, , .		0
215	INCREASED IL-18 RECEPTOR EXPRESSION IN COPD LUNG MACROPHAGES. , 2010, , .		0
216	Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research, 2010, 11, 122.	1.4	952

#	ARTICLE	IF	CITATIONS
217	Variants in FAM13A are associated with chronic obstructive pulmonary disease. <i>Nature Genetics</i> , 2010, 42, 200-202.	9.4	348
218	Mitochondrial DNA Polymorphisms Are Associated With COPD. , 2010, , .		0
219	A Genome-wide Association Study Identifies FAM13A As A COPD Susceptibility Locus. , 2010, , .		1
220	Exhaled Volatile Organic Compounds As Potential Biomarkers In Chronic Obstructive Pulmonary Disease. , 2010, , .		0
221	A Randomized, Placeboâ€Controlled Study of the Effects of the p38 MAPK Inhibitor SBâ€681323 on Blood Biomarkers of Inflammation in COPD Patients. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 94-100.	1.0	88
222	Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. <i>Analyst, The</i> , 2010, 135, 315.	1.7	119
223	Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. <i>Respiratory Research</i> , 2010, 11, 77.	1.4	134
224	Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2010, 363, 1128-1138.	13.9	2,359
225	Determinants of poor 6-min walking distance in patients with COPD: The ECLIPSE cohort. <i>Respiratory Medicine</i> , 2010, 104, 849-857.	1.3	171
226	The use of plethysmography and oscillometry to compare longâ€acting bronchodilators in patients with COPD. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 244-252.	1.1	68
227	Fluticasone Propionate Protects against Ozone-Induced Airway Inflammation and Modified Immune Cell Activation Markers in Healthy Volunteers. <i>Environmental Health Perspectives</i> , 2008, 116, 799-805.	2.8	52
228	A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: Upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. <i>Pulmonary Pharmacology and Therapeutics</i> , 2007, 20, 52-59.	1.1	48
229	Validation of the Human Ozone Challenge Model as a Tool for Assessing Anti-Inflammatory Drugs in Early Development. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 498-503.	1.0	38
230	More than just innate immunity: comparative analysis of <i>Chlamydomydia pneumoniae</i> and <i>Chlamydia trachomatis</i> effects on host-cell gene regulation. <i>Cellular Microbiology</i> , 2003, 5, 785-795.	1.1	44
231	Differences in pathogenicity of herpes simplex virus serotypes 1 and 2 may be observed by histopathology and high-resolution magnetic resonance imaging in a murine encephalitis model. <i>Journal of NeuroVirology</i> , 2001, 7, 105-116.	1.0	10
232	Effect of Famciclovir on Herpes Simplex Virus Type 1 Corneal Disease and Establishment of Latency in Rabbits. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2044-2053.	1.4	27
233	Identification and Initial Characterization of Four Novel Members of the Interleukin-1 Family. <i>Journal of Biological Chemistry</i> , 2000, 275, 10308-10314.	1.6	303
234	Herpes Simplex Virus Type 1 Glycoprotein E Domains Involved in Virus Spread and Disease. <i>Journal of Virology</i> , 2000, 74, 6712-6719.	1.5	43

#	ARTICLE	IF	CITATIONS
235	Role of p38 Mitogen-Activated Protein Kinase in Rhinovirus-Induced Cytokine Production by Bronchial Epithelial Cells. <i>Journal of Immunology</i> , 2000, 165, 5211-5220.	0.4	136
236	Analysis of Individual Human Trigeminal Ganglia for Latent Herpes Simplex Virus Type 1 and Varicella-Zoster Virus Nucleic Acids Using Real-Time PCR. <i>Journal of Virology</i> , 2000, 74, 11464-11471.	1.5	165
237	The Transcriptional Activation Domain of VP16 Is Required for Efficient Infection and Establishment of Latency by HSV-1 in the Murine Peripheral and Central Nervous Systems. <i>Virology</i> , 1999, 259, 20-33.	1.1	40
238	Toxicity and Neuronal Infection of a HSV-1 ICP34.5 Mutant in Nude Mice. <i>Journal of NeuroVirology</i> , 1998, 4, 100-105.	1.0	29
239	Use of Differential Display Reverse Transcription-PCR To Reveal Cellular Changes during Stimuli That Result in Herpes Simplex Virus Type 1 Reactivation from Latency: Upregulation of Immediate-Early Cellular Response Genes TIS7, Interferon, and Interferon Regulatory Factor-1. <i>Journal of Virology</i> , 1998, 72, 1252-1261.	1.5	26